Chromocell Therapeutics Corporation (CHRO) Company Long-Term Loans and Borrowings

Chromocell Therapeutics Corporation - graphic logo of issuer CHRO

The price action on the chart for Chromocell Therapeutics (CHRO), a developer of pain management therapies, reflects a metric of 0.00. Chromocell Therapeutics is implementing environmental standards in chemical synthesis and adhering to testing ethics. However, the business remains vulnerable due to a lack of profitability and potential research failures. Meanwhile, the sector continues to serve as a defensive asset, as the demand for new medications remains independent of economic crises.

CHRO Chromocell Therapeutics Corp.: Company Long-Term Debts in the range 02/21/2024 - 07/02/2025

Analytical breakdowns for Chromocell Therapeutics

- price and consensus price forecast:
Stock Price chromocell.com|CHRO - Price Target Chart
- market capitalization data:
Market Value Chromocell Therapeutics|CHRO - Total Company Value
- book capitalization data:
Net Asset Value per Share Chromocell Therapeutics|CHRO - Book Capitalization|Market Cap to Net Assets Ratio chromocell.com|CHRO - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Chromocell Therapeutics|CHRO - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Chromocell|CHRO - Company Debts|Debts to Book Value Chromocell Therapeutics|CHRO - Company Long-Term Debt|Company Current Liabilities Chromocell Therapeutics
Fundamental valuation:chromocell.com (CHRO)
Manufactured products of Chromocell

An analysis of the debt sustainability of Chromocell Therapeutics (CHRO) allows for an assessment of the business's financial stability amid market volatility. The development of non-opioid analgesics in partnership with clinics requires significant capital expenditures. The time series of the organization's long-term financial debt compares the issuer's credit load against US industry benchmarks. A sharp increase in loan volume signals overheating and the risk of insolvency. Exceeding borrowing limits necessitates a prompt reduction of the asset's share within the portfolio.

Competitor analysis for Chromocell Therapeutics

biogen.com - Company Long-Term Debts|Company Long-Term Debt Neurocrine Biosciences, Inc. (NBIX)|RGC: Company Long-Term Loans and Borrowings|Company Long-Term Debt AXSM|ACADIA Corp (ACAD) - Long-Term Debt|Company Long-Term Debts XENE|Company Long-Term Liabilities vikingtherapeutics.com|Supernus (SUPN) - Company Long-Term Debts|Company Long-Term Loans and Borrowings CPRX (Catalyst Pharma)|Company Long-Term Debt Denali Therapeutics Inc|Harmony Corp - Company Long-Term Loans and Borrowings|BHVN (Biohaven Ltd.) - Company Long-Term Debt|AMLX: Long-Term Debt|TRVI (Trevi Therapeutics, Inc.) - Company Long-Term Debt|PRAX (Praxis Precision Medicines Inc) - Company Long-Term Liabilities|Company Long-Term Debt AVXL (Anavex Corp)|Long-Term Debt CeriBell EEG|Company Long-Term Debts PRTA (Prothena)|Company Long-Term Liabilities alector.com (ALEC)|ANNX: Company Long-Term Debts|Omeros Corp - Long-Term Debt|NGNE - Company Long-Term Debt|ACIU: Company Long-Term Debt|Voyager Therapeutics (VYGR) - Company Long-Term Debt|Company Long-Term Debt neumoratx.com|SCLX - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings Tevogen Bio Holdings Inc. (TVGN)|Company Long-Term Liabilities Alpha Cognition|Amount of Long-Term Liabilities cogrx.com (CGTX)|Company Long-Term Debts Inhibikase Therapeutics|Company Long-Term Loans and Borrowings cassavasciences.com SAVA|ASRT (Assertio Therapeutics) - Company Long-Term Debts|COYA: Long-Term Debt|Company Long-Term Debt vistagen.com VTGN|Ovid Therapeutics (OVID) - Company Long-Term Loans and Borrowings|ABOS (Acumen Pharmaceuticals) - Company Long-Term Debts|Company Long-Term Debts CRVO|ATHE - Company Long-Term Debt|Long-Term Liabilities clene.com (CLNN)|PEPG: Company Long-Term Debts|JUNS - Long-Term Debt|Relmada Therapeutics - Company Long-Term Liabilities|annovisbio.com (ANVS) - Company Long-Term Debts|GRCE - Company Long-Term Liabilities|Firefly Neuroscience, Inc. (AIFF) - Amount of Long-Term Liabilities|KLTO: Company Long-Term Debts|Long-Term Debt Volume NeuroSense Therapeutics, Ltd.|Company Long-Term Debts RVPH (Reviva Pharmaceuticals)|Company Long-Term Liabilities MTVA (metaviatx.com)|Company Long-Term Debt NRXS|Long-Term Debt Volume Helius Medical Technologies, Inc. HSDT|PASG: Company Long-Term Debts|NEUP - Company Long-Term Liabilities|Company Long-Term Debts Minerva Neurosciences NERV|ATHA (athira.com) - Company Long-Term Loans and Borrowings|ADXN - Company Long-Term Debt|Company Long-Term Loans and Borrowings ALZN|Cyclerion Therapeutics - Company Long-Term Debt|Long-Term Debt PTIX (protagenic.com)|KTTA - Company Long-Term Debt|Company Long-Term Indebtedness Cortigent Inc CRGT|ATXI (Avenue Therapeutics, Inc.) - Company Long-Term Debts|Brainstorm Cell Therapeutics Inc. (BCLI) - Long-Term Debt|CARA: Company Long-Term Liabilities|ELYM (Eliem Therapeutics Inc.) - Company Long-Term Debts|ITCI - Company Long-Term Debt|Company Long-Term Loans and Borrowings LBPH|Marinus Pharmaceuticals, Inc. - Company Long-Term Debt|Long-Term Debt NKGen Biotech Inc (NKGN)|NeuroBo - Company Long-Term Debts|Company Long-Term Liabilities Sage Therapeutics Inc SAGE|Company Long-Term Debts Synaptogenix, Inc. (SNPX)|TRVN: Company Long-Term Loans and Borrowings|Company Long-Term Debt vigilneuro.com VIGL|WENA (Anew Medical Inc.) - Company Long-Term Loans and Borrowings|Company Long-Term Debt CERE (Cerevel)